Gilead Sciences (GILD) Misses Q1 EPS by 19c, Reiterates FY Guidance

Go back to Gilead Sciences (GILD) Misses Q1 EPS by 19c, Reiterates FY Guidance

Gilead Sciences (GILD) PT Lowered to $90 at RBC Capital

May 2, 2018 8:26 AM EDT

RBC Capital lowered its price target on Gilead Sciences (NASDAQ: GILD) to $90.00 (from $94.00) while maintaining an Outperform rating following a disappointing quarter.

... More

Gilead Sciences (GILD) PT Lowered to $79 at Baird

May 2, 2018 7:51 AM EDT

Baird lowered its price target on Gilead Sciences (NASDAQ: GILD) to $79.00 (from $87.00) while maintaining an Outperform rating on weaker than expected 1Q.

Analyst Brian Skorney commented, "While investors had projected 2018 as a trough earnings year for the company, worse than expected sales... More

Gilead Sciences (GILD) PT Lowered to $81 at Morgan Stanley

May 2, 2018 7:45 AM EDT

Morgan Stanley lowered its price target on Gilead Sciences (NASDAQ: GILD) to $81.00 (from $85.00) while maintaining a Equalweight rating following the company's 1Q earnings report.

1Q18 EPS missed by $0.17. The miss was driven by lower than expected total revenues ($5.1B vs. $5.4B... More